Ongoing Research Projects

1. Title: Focused ultrasound modulation of neuromelanin accumulation in a humanized rat model of Parkinson’s disease
Principal Investigator: Miquel Vila
Agency: Network of Centres of Excellence in Neurodegeneration (CoEN)
Funding: 456,488 € (Vila group: 182,097.52 €)
Period: 2018-20

2. Title: Pathogenic Role of Neuromelanin in Parkinson’s disease and Brain Aging: Molecular Mechanisms in a Novel Humanized Pre-clinical in Vivo Model
Principal Investigator: Miquel Vila
Agency: The Michael J. Fox Foundation for Parkinson’s Research (USA)
Funding: $98,450
Period: 2018-19

3. Title: Diagnostic/therapeutic potential of neuromelanin in Parkinson disease using novel humanized preclinical in vivo model
Principal Investigator: Miquel Vila
Agency: Ministerio de Economía y Competitividad (MINECO, Spain)
Funding: 363,000 €
Period: 2016-20

4. Title: Identification of pathophysiological biomarkers in the prodromal/preclinical phase of Parkinson’s disease
Principal Investigator: Miquel Vila
Agency: Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED, Spain)
Funding: 280,000 € (Vila group: 70,000 €)
Period: 2017-18

5. Title: Support to Consolidated Research Groups
Principal Investigator: Miquel Vila
Agency: Agència de Gestió d’Ajuts Universitaris i de la Recerca (AGAUR, Spain)
Funding: 35,200 €
Period: 2017-19

6. Title: A precise approach for nucleoside-based therapy of neuromuscular disorders with defects in mitochondrial DNA
Co-Principal Investigator: Miquel Vila (Coordinator: M.A. Martín, Hospital 12 de Octubre)
Agency: ISCIII-FEDER, Programa Desarrollo en Medicina Personalizada (Spain)
Funding: 806,223 € (Vila group: 58,000 €)
Period: 2016-19

7. Title: Adaptive immune response in Parkinson’s disease induced by alpha-synuclein proteoforms present in Lewy bodies: diagnostic and therapeutic application
Principal Investigator: Jordi Bové
Agency: Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (Spain)
Funding: 134,915 €
Period: 2016-18

8. Title: Targeting a novel transcriptional pathway to reduce alpha-synuclein expression
Co-Principal Investigator: Miquel Vila (PI: S. Desagher, CNRS-Institute of Molecular Genetics Montpellier, France)
Agency: The Michael J. Fox Foundation for Parkinson’s Research (USA)
Funding: 91,400 € (Vila group: 26,624 €)
Period: 2016-18

9. Title: Pathogenic role of autophagic/lysosomal dysfunction in Parkinson’s disease: diagnosis and new preclinical therapies.
Principal Investigator: Marta Martínez-Vicente
Agency: Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (Spain)
Funding: 110,715 €
Period: 2015-17

10. Title: Transcriptional profiling in prodromal subgroups of Parkinson’s disease
Principal Investigator: Ariadna Laguna
Agency: Fundación Tatiana Pérez de Guzmán el Bueno (Spain)
Funding: 40,000 €
Period: 2015-17

11. Title: New therapeutic strategies for the treatment of synucleinopathies
Collaborator: Miquel Vila (PI: R. Revilla, nLife Therapeutics, Spain)
Agency: Retos-Colaboración, MINECO (Spain)
Funding: 1,971,513 € (Vila group: 368,114 €)
Period: 2014-17

12. Title: Role of the cellular prion protein as “cross-talk” protein between alpha-syn/LRRK2 and p-Tau in sporadic and familiar Parkinson’s disease
Collaborator: Miquel Vila (PI: J.A. del Río, The Institute for Bioengineering of Catalonia, Spain)
Agency: Marató de TV3 Foundation (Spain)
Funding: 195,646 €
Period: 2014-17

13. Title: Targeting the transcriptional regulator of autophagy LMX1B for Parkinson’s disease therapeutic development
Principal Investigator: Ariadna Laguna
Agency: The Michael J. Fox Foundation for Parkinson’s Research (USA)
Funding: 91,400 €
Period: 2015-16

14. Title: Role of alpha-synuclein and neuromelanin in the initiation and extension of Parkinson’s disease: therapeutic and diagnosis potential in novel pre-clinical models
Principal Investigator: Miquel Vila
Agency: Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (Spain)
Funding: 142,780 €
Period: 2014-16

15. Title: Pharmacokinetic and pharmacodynamic characterization of a novel therapy to silence selectively alpha-synuclein in monoaminergic neurons of rat.
Collaborator: Miquel Vila (PI: R. Revilla, nLife Therapeutics, Spain)
Agency: The Michael J. Fox Foundation for Parkinson’s Research (USA)
Funding: 353,694 € (Vila group: 30,000 €)
Period: 2014-16

16. Title: Support to Consolidated Research Groups
Co-Principal Investigator: Miquel Vila (Coordinator: J.X. Comella, VHIR, Spain)
Agency: Agència de Gestió d’Ajuts Universitaris i de la Recerca (AGAUR, Spain)
Funding: 30,000 €
Period: 2014-16

17. Mitochondrial dysfunction in Parkinson’s disease: role of mitochondrial dynamics
Principal Investigator: Celine Perier
Agency: Ministerio de Economía y Competitividad (MINECO, Spain)
Funding: 114,950 €
Period: 2014-2016

18. Title: Prion-like dissemination of synuclein pathology: a non-human primate study
Co-Principal Investigator: Miquel Vila (PI: E. Bezard, Université de Bordeaux, France)
Agency: The Michael J. Fox Foundation for Parkinson’s Research (USA)
Funding: 374,375 €
Period: 2013-16

19. Title: Regenerating dopaminergic neurons in Parkinson’s disease via cell-fusion-mediated reprogramming
Co-Principal Investigator: Miquel Vila (Coordinator: P. Cosma, CRG, Spain)
Agency: Marató de TV3 Foundation (Spain)
Funding: 300,000 € (Vila group: 150,000 €)
Period: 2013-16